New Triple-Threat treatment aims to hold back recurrent ovarian cancer
NCT ID NCT04742075
Summary
This study is testing whether adding two newer drugs (an immunotherapy and a vaccine) to a standard maintenance pill can better control recurrent ovarian cancer. It involves 188 women whose cancer has returned but responded to platinum chemotherapy and who do not have specific BRCA gene mutations. The goal is to see if this combination can keep the cancer from progressing longer than the standard single-drug therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rigshospitalet
København Ø, Region Sjælland, 2100, Denmark
Conditions
Explore the condition pages connected to this study.